Compare UEIC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | BNR |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 38.3M |
| IPO Year | 1993 | 2020 |
| Metric | UEIC | BNR |
|---|---|---|
| Price | $3.23 | $22.02 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | ★ 148.9K | 51.5K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $390,997,000.00 | $75,749,382.00 |
| Revenue This Year | $0.57 | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.35 | ★ 5.56 |
| 52 Week Low | $2.69 | $2.18 |
| 52 Week High | $12.50 | $23.45 |
| Indicator | UEIC | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 75.06 |
| Support Level | $3.06 | $14.01 |
| Resistance Level | $3.36 | $23.45 |
| Average True Range (ATR) | 0.19 | 2.03 |
| MACD | 0.08 | 0.79 |
| Stochastic Oscillator | 75.70 | 85.90 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.